Here are three facts:
1. Signafuse received FDA 510(k) clearance in 2014 as bone void filler for standalone use in posterolateral spine fusion procedures.
2. Signafuse is a moldable bone graft comprised of patented bioactive glass particles and biphasic mineral granules suspended in a patented resorbable polymer carrier.
3. BioStructures is a medical device company focused on developing proprietary platforms in bioresorbable bone graft products for a range of spinal and orthopedic fusion procedures.
More articles on devices:
NuVasive reaches definitive settlement with US: 5 points
Is Stryker next for a big transaction? 7 key notes
Amendia acquires Custom Spine — 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
